Clinical immunology (Orlando, Fla.) · 2026
Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiao Xiang, Zeng Qiuming, Ouyang Song, Lu Wei, Hu Zhaolan, Liang Yong, Jin Wanlin, He Dan, Jiang Wei, Li Miao, Chen Juan, Yan Jianhui, Yin Weifan
Аннотация
OBJECTIVE: To assess the efficacy and safety of telitacicept in myasthenia gravis (MG), focusing on elderly patients.
METHODS: Sixteen MG patients receiving weekly telitacicept (160 mg) for 3 months were retrospectively analyzed.
RESULTS: Telitacicept significantly improved Myasthenia Gravis Activities of Daily Living (MG-ADL), from 7.31 ± 5.02 to 1.13 ± 1.20 (p < 0.001), and Quantitative Myasthenia Gravis (QMG), from 14.81 ± 7.04 to 4.75 ± 2.27 (p < 0.001). Although not statistically significant, elderly patients showed a trend toward greater reductions in MG-ADL (-5.43 vs -3.56 at 1 month, p = 0.41; -7.29 vs -5.33 at 3 months, p = 0.54) and QMG (-8.86 vs -5.33 at 1 month, p = 0.32; -11.14 vs -9.22 at 3 months, p = 0.65). Minimal symptom expression (MSE) was 81.25%, reaching 100% in elderly patients. Immunoglobulin levels (p < 0.001), CD19+ B-cell percentages (p < 0.01), autoantibody titers (p < 0.01), and corticosteroid dosage (p < 0.05) decreased significantly.
CONCLUSION: Telitacicept is a safe, effective MG add-on therapy. Elderly patients show a potential trend toward greater improvement, warranting larger studies.
METHODS: Sixteen MG patients receiving weekly telitacicept (160 mg) for 3 months were retrospectively analyzed.
RESULTS: Telitacicept significantly improved Myasthenia Gravis Activities of Daily Living (MG-ADL), from 7.31 ± 5.02 to 1.13 ± 1.20 (p < 0.001), and Quantitative Myasthenia Gravis (QMG), from 14.81 ± 7.04 to 4.75 ± 2.27 (p < 0.001). Although not statistically significant, elderly patients showed a trend toward greater reductions in MG-ADL (-5.43 vs -3.56 at 1 month, p = 0.41; -7.29 vs -5.33 at 3 months, p = 0.54) and QMG (-8.86 vs -5.33 at 1 month, p = 0.32; -11.14 vs -9.22 at 3 months, p = 0.65). Minimal symptom expression (MSE) was 81.25%, reaching 100% in elderly patients. Immunoglobulin levels (p < 0.001), CD19+ B-cell percentages (p < 0.01), autoantibody titers (p < 0.01), and corticosteroid dosage (p < 0.05) decreased significantly.
CONCLUSION: Telitacicept is a safe, effective MG add-on therapy. Elderly patients show a potential trend toward greater improvement, warranting larger studies.